NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 48.9% in January

NextCure, Inc. (NASDAQ:NXTC) saw a significant increase in short interest in January. As of January 15th, there was short interest totaling 48,377 shares, an increase of 48.9% from the December 31st total of 32,483 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average daily volume of 32,544 shares, the days-to-cover ratio is currently 1.5 days. Based on an average daily volume of 32,544 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.6% of the shares of the stock are sold short.

NextCure Trading Up 0.7%

Shares of NASDAQ:NXTC opened at $10.93 on Tuesday. NextCure has a 1-year low of $2.69 and a 1-year high of $15.74. The stock has a market capitalization of $38.32 million, a P/E ratio of -0.45 and a beta of 1.52. The business has a 50-day moving average price of $12.50 and a two-hundred day moving average price of $8.86.

NextCure (NASDAQ:NXTC) last issued its earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.06) by $0.84. As a group, equities analysts predict that NextCure will post -1.87 EPS for the current year.

Analyst Ratings Changes

NXTC has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research note on Wednesday, January 28th. LADENBURG THALM/SH SH raised shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Friday, November 7th. Finally, Wall Street Zen upgraded shares of NextCure to a “hold” rating in a research report on Saturday, December 13th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP lifted its stake in NextCure, Inc. (NASDAQ:NXTC) by 13.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the period. Cable Car Capital LP owned 28.29% of NextCure worth $349,000 at the end of the most recent quarter. 42.65% of the stock is currently owned by institutional investors.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.